-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ruxoprubart in Glomerulonephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ruxoprubart in Glomerulonephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ruxoprubart in Glomerulonephritis Drug Details: Ruxoprubart (NM-8074) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ruxoprubart in Paroxysmal Nocturnal Hemoglobinuria
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ruxoprubart in Paroxysmal Nocturnal Hemoglobinuria report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ruxoprubart in Paroxysmal Nocturnal Hemoglobinuria Drug Details: Ruxoprubart (NM-8074) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cabometyx in Urethral Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cabometyx in Urethral Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cabometyx in Urethral Cancer Drug Details: Cabozantinib s-malate (Cabometyx, Aptimetyx) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cabometyx in Ureter Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cabometyx in Ureter Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cabometyx in Ureter Cancer Drug Details: Cabozantinib s-malate (Cabometyx, Aptimetyx) is a...
-
Product Insights
Thrombotic Microangiopathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Thrombotic Microangiopathy - Drugs In Development, 2023’, provides an overview of the Thrombotic Microangiopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thrombotic Microangiopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Membranous Glomerulonephritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Membranous Glomerulonephritis - Drugs In Development, 2023’, provides an overview of the Membranous Glomerulonephritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Membranous Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) - Drugs In Development, 2023’, provides an overview of the Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Choroidal Neovascularization – Drugs In Development, 2023
Global Markets Direct’s, ‘Choroidal Neovascularization - Drugs In Development, 2023’, provides an overview of the Choroidal Neovascularization pipeline landscape. The report provides comprehensive information on the therapeutics under development for Choroidal Neovascularization, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Dermatomyositis – Drugs In Development, 2023
Global Markets Direct’s, ‘Dermatomyositis - Drugs In Development, 2023’, provides an overview of the Dermatomyositis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dermatomyositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Hemolytic Uremic Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Hemolytic Uremic Syndrome - Drugs In Development, 2023’, provides an overview of the Hemolytic Uremic Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemolytic Uremic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...